Provided by Tiger Trade Technology Pte. Ltd.

Vaxcyte, Inc.

66.96
+0.26000.39%
Post-market: 66.60-0.3600-0.54%19:47 EDT
Volume:11.56M
Turnover:763.14M
Market Cap:9.96B
PE:-8.75
High:67.15
Open:65.86
Low:64.27
Close:66.70
52wk High:90.75
52wk Low:39.87
Shares:148.81M
Float Shares:136.00M
Volume Ratio:1.92
T/O Rate:8.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.6496
EPS(LYR):-5.6333
ROE:-36.51%
ROA:-22.61%
PB:3.61
PE(LYR):-11.89

Loading ...

Vaxcyte is Maintained at Buy by Guggenheim

Dow Jones
·
Oct 05

Sector Update: Healthcare

MT Newswires Live
·
Oct 05

S&P 500 Futures Decline in Premarket Trading; Vaxcyte, PTC Lead

Dow Jones
·
Oct 05

Vaxcyte price target raised to $125 from $116 at Guggenheim

TIPRANKS
·
Oct 05

Top Premarket Gainers

MT Newswires Live
·
Oct 05

Vaxcyte Reports Bacterial-Infection Vaccine Met Primary Endpoints in Phase 3 Trial

Dow Jones
·
Oct 05

U.S. Stocks on the MOVE-Estée Lauder, PTC, Vaxcyte

Reuters
·
Oct 05

Vaxcyte Surges on Pneumococcal Vaccine Late-Stage Trial Success

Reuters
·
Oct 05

Vaxcyte Shares Surge as Pneumococcal Vaccine Meets Main Trial Goals

Reuters
·
Oct 05

Vaxcyte announces ‘positive’ results from OPUS-1 Phase 3 trial of VAX-31

TIPRANKS
·
Oct 05

Vaxcyte Shares Jump 25.6% Premarket After Co's Pneumococcal Vaccine Meets Late-Stage Trial Goals

THOMSON REUTERS
·
Oct 05

Vaxcyte - Vax-31 Meets All Prespecified Primary Endpoints Across Age Groups Compared to Pcv20 And/or Pcv21

THOMSON REUTERS
·
Oct 05

Vaxcyte, Inc.: to Report Results from Opus-2 and Opus-3 Adult Phase 3 Trials in First Half of 2027

THOMSON REUTERS
·
Oct 05

Vaxcyte - Vax-31 Meets Noninferiority for All 32 Serotype Comparisons in Adults 18-49 vs 50-64

THOMSON REUTERS
·
Oct 05

Vaxcyte Reports Positive Topline Data from Opus-1, the Pivotal Adult Phase 3 Trial of Vax-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

THOMSON REUTERS
·
Oct 05

Vaxcyte Sets Oct. 5 Webcast to Release Phase 3 OPUS-1 Topline Data for VAX-31 Pneumococcal Vaccine Candidate

Reuters
·
Oct 05

Vaxcyte EVP, Chief Scientific Officer and COO Jim Wassil Disposes of USD 127,561 in Common Shares

Reuters
·
Oct 03

Mizuho biotech analysts hold an analyst/industry conference call

TIPRANKS
·
Oct 02

Vaxcyte Price Target Cut to $130.00/Share from $133.00 by B of a Securities

Dow Jones
·
Sep 29

Vaxcyte VAX-31 Positioned to Validate Broad Coverage, BofA Says

MT Newswires Live
·
Sep 28